Venetoclax (Venclyxto®) Horizons Infosheet

This Horizons Infosheet provides information about Venetoclax (Venclyxto®), a drug being investigated for the treatment of patients with the t(11;14) type of myeloma.

This Horizon Infosheet covers key questions about Venetoclax (Venclyxto®), such as:

  • What is venetoclax and how does it work?
  • Why is venetoclax being investigated for t(11;14) myeloma only?
  • How is venetoclax given?
  • What evidence supports the use of venetoclax?
  • What are the possible side effects of venetoclax?
  • Is venetoclax currently available in any UK clinical trials?
  • What is the availability of venetoclax in the UK?
  • What are the future directions of research for venetoclax?

Key points you can read about in this Horizons Infosheet include:

  • Venetoclax is a drug that is being investigated for the treatment of myeloma
  • Venetoclax is one of a new class of drugs for myeloma called ‘pro-survival inhibitors’, which work by speeding up cancer cell death
  • Venetoclax is being investigated for treatment of patients with the t(11;14) genetic type of myeloma. Clinical trials have indicated that it is most effective in this subgroup of patients
  • Side effects seen so far with venetoclax have included reductions in blood cells, infections, and effects on the digestive system
  • Venetoclax is not available for use on the NHS for myeloma. However, patients may be treated with it as part of a clinical trial

Venetoclax Horizons Infosheet

PDF / 199KB Download
Close-up photograph of a hand holding a mobile phone.

Stay in touch

We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.